01 18ASTRAZENECA AB
01 188501698
01 18Blank
01 17Y
02 1Blank
01 182027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-1976
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 202293
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-1977
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 205649
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim :
Application Number : 209210
Patent Use Code : U-2588
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 202293
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
